SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ — Tanezumab, a humanized monoclonal antibody that targets nerve-growth factor, reduced pain in three common pain conditions, according to the results from three phase two studies presented today in a single poster at the American Academy of Pain Medicine’s 26th Annual Meeting.
Read more here:
Tanezumab Demonstrated Analgesic Efficacy Across Three Pain Conditions in Phase Two Studies (PR Newswire via Yahoo! News)
